Cited 11 times in
Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 손주혁 | - |
dc.date.accessioned | 2024-03-22T06:12:58Z | - |
dc.date.available | 2024-03-22T06:12:58Z | - |
dc.date.issued | 2023-08 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/198457 | - |
dc.description.abstract | Background: Approximately 80% of all breast cancers (BCs) are currently categorized as human epidermal growth factor receptor 2 (HER2)-negative [immunohistochemistry (IHC) 0, 1+, or 2+/in situ hybridization (ISH) negative]; approximately 60% of BCs traditionally categorized as HER2-negative express low levels of HER2. HER2-low (IHC 1+ or IHC 2+/ISH−) status became clinically actionable with approval of trastuzumab deruxtecan to treat unresectable/metastatic HER2-low BC. Greater understanding of patients with HER2-low disease is urgently needed. Patients and methods: This global, multicenter, retrospective study (NCT04807595) included tissue samples from patients with confirmed HER2-negative unresectable/metastatic BC [any hormone receptor (HR) status] diagnosed from 2014 to 2017. Pathologists rescored HER2 IHC-stained slides as HER2-low (IHC 1+ or IHC 2+/ISH−) or HER2 IHC 0 after training on low-end expression scoring using Ventana 4B5 and other assays at local laboratories (13 sites; 10 countries) blinded to historical scores. HER2-low prevalence and concordance between historical scores and rescores were assessed. Demographics, clinicopathological characteristics, treatments, and outcomes were examined. Results: In rescored samples from 789 patients with HER2-negative unresectable/metastatic BC, the overall HER2-low prevalence was 67.2% (HR positive, 71.1%; HR negative, 52.8%). Concordance was moderate between historical and rescored HER2 statuses (81.3%; κ = 0.583); positive agreement was numerically higher for HER2-low (87.5%) than HER2 IHC 0 (69.9%). More than 30% of historical IHC 0 cases were rescored as HER2-low overall (all assays) and using Ventana 4B5. There were no notable differences between HER2-low and HER2 IHC 0 in patient characteristics, treatments received, or clinical outcomes. Conclusions: Approximately two-thirds of patients with historically HER2-negative unresectable/metastatic BC may benefit from HER2-low-directed treatments. Our data suggest that HER2 reassessment in patients with historical IHC 0 scores may be considered to help optimize selection of patients for treatment. Further, accurate identification of patients with HER2-low BC may be achieved with standardized pathologist training. © 2023 The Author(s) | - |
dc.description.statementOfResponsibility | restriction | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | BMJ | - |
dc.relation.isPartOf | ESMO OPEN | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Biomarkers, Tumor* | - |
dc.subject.MESH | Breast Neoplasms* / diagnosis | - |
dc.subject.MESH | Breast Neoplasms* / epidemiology | - |
dc.subject.MESH | Breast Neoplasms* / therapy | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | In Situ Hybridization | - |
dc.subject.MESH | Prevalence | - |
dc.subject.MESH | Receptor, ErbB-2 / genetics | - |
dc.subject.MESH | Retrospective Studies | - |
dc.title | Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | G Viale | - |
dc.contributor.googleauthor | M Basik | - |
dc.contributor.googleauthor | N Niikura | - |
dc.contributor.googleauthor | E Tokunaga | - |
dc.contributor.googleauthor | S Brucker | - |
dc.contributor.googleauthor | F Penault-Llorca | - |
dc.contributor.googleauthor | N Hayashi | - |
dc.contributor.googleauthor | J Sohn | - |
dc.contributor.googleauthor | R Teixeira de Sousa | - |
dc.contributor.googleauthor | A M Brufsky | - |
dc.contributor.googleauthor | C S O'Brien | - |
dc.contributor.googleauthor | F Schmitt | - |
dc.contributor.googleauthor | G Higgins | - |
dc.contributor.googleauthor | D Varghese | - |
dc.contributor.googleauthor | G D James | - |
dc.contributor.googleauthor | A Moh | - |
dc.contributor.googleauthor | A Livingston | - |
dc.contributor.googleauthor | V de Giorgio-Miller | - |
dc.identifier.doi | 10.1016/j.esmoop.2023.101615 | - |
dc.contributor.localId | A01995 | - |
dc.relation.journalcode | J03799 | - |
dc.identifier.eissn | 2059-7029 | - |
dc.identifier.pmid | 37562195 | - |
dc.subject.keyword | HER2-low | - |
dc.subject.keyword | breast cancer | - |
dc.subject.keyword | human epidermal growth factor receptor 2 | - |
dc.subject.keyword | immunohistochemistry | - |
dc.subject.keyword | prevalence | - |
dc.subject.keyword | retrospective study. | - |
dc.contributor.alternativeName | Sohn, Joo Hyuk | - |
dc.contributor.affiliatedAuthor | 손주혁 | - |
dc.citation.volume | 8 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 101615 | - |
dc.identifier.bibliographicCitation | ESMO OPEN, Vol.8(4) : 101615, 2023-08 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.